BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27187778)

  • 1. Assessment of the Tumor Redox Status in Head and Neck Cancer by 62Cu-ATSM PET.
    Tsujikawa T; Asahi S; Oh M; Sato Y; Narita N; Makino A; Mori T; Kiyono Y; Tsuchida T; Kimura H; Fujieda S; Okazawa H
    PLoS One; 2016; 11(5):e0155635. PubMed ID: 27187778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing tumor hypoxia in head and neck cancer by PET with ⁶²Cu-diacetyl-bis(N⁴-methylthiosemicarbazone).
    Sato Y; Tsujikawa T; Oh M; Mori T; Kiyono Y; Fujieda S; Kimura H; Okazawa H
    Clin Nucl Med; 2014 Dec; 39(12):1027-32. PubMed ID: 25140555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redox reaction and clinical outcome of primary diffuse large B-cell lymphoma of the central nervous system: Prognostic role of metabolic and textural parameters of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/computed tomography in a small patient cohort.
    Tsuchiya J; Yoneyama T; Ohtake M; Tateishi K; Bae H; Kishino M; Tateishi U
    Nucl Med Commun; 2020 Jun; 41(6):567-574. PubMed ID: 32371672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of
    Toriihara A; Ohtake M; Tateishi K; Hino-Shishikura A; Yoneyama T; Kitazume Y; Inoue T; Kawahara N; Tateishi U
    Ann Nucl Med; 2018 May; 32(4):264-271. PubMed ID: 29453680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator.
    Wong TZ; Lacy JL; Petry NA; Hawk TC; Sporn TA; Dewhirst MW; Vlahovic G
    AJR Am J Roentgenol; 2008 Feb; 190(2):427-32. PubMed ID: 18212229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer.
    Takahashi N; Fujibayashi Y; Yonekura Y; Welch MJ; Waki A; Tsuchida T; Sadato N; Sugimoto K; Itoh H
    Ann Nucl Med; 2000 Oct; 14(5):323-8. PubMed ID: 11108159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study.
    Minagawa Y; Shizukuishi K; Koike I; Horiuchi C; Watanuki K; Hata M; Omura M; Odagiri K; Tohnai I; Inoue T; Tateishi U
    Ann Nucl Med; 2011 Jun; 25(5):339-45. PubMed ID: 21327756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers.
    Kositwattanarerk A; Oh M; Kudo T; Kiyono Y; Mori T; Kimura Y; Maruyama R; Fujibayashi Y; Fujieda S; Okazawa H
    Clin Nucl Med; 2012 Mar; 37(3):252-7. PubMed ID: 22310251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia.
    Takahashi N; Fujibayashi Y; Yonekura Y; Welch MJ; Waki A; Tsuchida T; Sadato N; Sugimoto K; Nakano A; Lee JD; Itoh H
    Ann Nucl Med; 2001 Jun; 15(3):293-6. PubMed ID: 11545205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paired 18F-Fluorodeoxyglucose (18F-FDG), and 64Cu-Copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) (64Cu-ATSM) PET Scans in Dogs with Spontaneous Tumors and Evaluation for Hypoxia-Directed Therapy.
    Maitz CA; Tate D; Bechtel S; Lunceford J; Henry C; Flesner B; Collins A; Varterasian M; Tung D; Zhang L; Saha S; Bryan JN
    Radiat Res; 2022 Mar; 197(3):253-260. PubMed ID: 34855934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.
    Lohith TG; Kudo T; Demura Y; Umeda Y; Kiyono Y; Fujibayashi Y; Okazawa H
    J Nucl Med; 2009 Dec; 50(12):1948-53. PubMed ID: 19910425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
    Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
    J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.
    Zhang T; Das SK; Fels DR; Hansen KS; Wong TZ; Dewhirst MW; Vlahovic G
    AJR Am J Roentgenol; 2013 Nov; 201(5):W698-706. PubMed ID: 24147499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.
    Tateishi K; Tateishi U; Sato M; Yamanaka S; Kanno H; Murata H; Inoue T; Kawahara N
    AJNR Am J Neuroradiol; 2013 Jan; 34(1):92-9. PubMed ID: 22700754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of 64Cu-ATSM in head and neck cancer: a preliminary prospective study.
    Grassi I; Nanni C; Cicoria G; Blasi C; Bunkheila F; Lopci E; Colletti PM; Rubello D; Fanti S
    Clin Nucl Med; 2014 Jan; 39(1):e59-63. PubMed ID: 24097008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy.
    Seol YM; Kwon BR; Song MK; Choi YJ; Shin HJ; Chung JS; Cho GJ; Lee JC; Lee BJ; Wang SG; Kim HJ; Kim WT; Kim SJ; Yun EY
    Acta Oncol; 2010; 49(2):201-8. PubMed ID: 20100156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.